Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago CAR-T

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan

Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas.

Thomas, a 54-year-old patient from Switzerland, has been battling multiple myeloma for nearly ten years. Initially diagnosed in 2016, he has endured severe bone pain and undergone multiple rounds of systemic chemotherapy and monoclonal antibody therapy. Although his condition was temporarily controlled, repeated relapses, with the most recent in 2022, made treatment increasingly challenging.

However, the global development of CAR-T therapy has reignited hope. The introduction of FUCASO (Eque-cel), the first fully human CAR-T product in mainland China, has brought new light to Thomas. This groundbreaking treatment not only boasts low immunogenicity but also offers prolonged efficacy, enabling patients to return to a high quality of life.

Thomas ultimately chose to receive the cutting-edge CAR-T therapy at Tongji Hospital, seeking a fundamental breakthrough in his treatment. The apheresis procedure was conducted by the hospital’s top hematology team, who possess international-level expertise and place special emphasis on patient-specific needs and treatment safety. The attending physician elaborated on the apheresis process in an interview, saying, “We precisely collected T-cells from Thomas’s body, then modified these cells in a controlled environment to specifically target multiple myeloma cancer cells. The use of FUCASO greatly enhanced the treatment’s specificity and success rate.”

Thomas expressed high recognition and appreciation for the hospital team’s professionalism and the transparency of the treatment process. Tongji Hospital leveraged its advanced technology and equipment to provide Thomas with a smooth and efficient apheresis experience, ensuring high-quality T-cell collection and paving the way for the subsequent treatment.

Thomas is now filled with confidence and anticipation, looking forward to the new life that CAR-T therapy promises. This new beginning marks a significant step in his treatment journey, injecting new hope into his path to recovery.

We will continue to follow up on the patient’s subsequent treatment and report on the progress.

CART MultipleMyeloma FUCASOJourney Equecel TongjiHospital CancerSurvivor BloodCancer Immunotherapy FullyHumanCART CancerTreatment

4 months ago patient story

Ключевой этап точечного лечения: Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи

Ключевой этап точечного лечения:

Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи

Владимир Борзенков, 68-летний пациент из Санкт-Петербурга, в последнее время прошел важный этап лечения CAR-T в Международной больнице Жияхуи в Шанхае – аферез. Этот процесс включает в себя сбор Т-клеток из организма пациента для дальнейшей генетической модификации и увеличения. Владимир выразил благодарность профессионализму лечебной команды и прозрачности лечебного процесса, что не только сняло его беспокойство, но и увеличило уверенность в успехе лечения. Больница Жияхуи использовала свои передовые устройства и технологии, чтобы обеспечить Владимиру плавный и эффективный опыт афереза, гарантируя высококачественный сбор Т-клеток и заложив прочный фундамент для следующих этапов лечения.

#CART #МножественнаяМиелома #ОдобрениеФУКАСО #Эквесел #БольницаЖияхуи #Шанхай #ВыжившийОтРака #КровяноеРак #Иммунотерапия #ПолностьюЧеловеческийCART

#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART

4 months ago patient story , CAR-T

Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai

Title:

Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai

Content:

Vladimir Borzenkov, a 68-year-old Russian patient from Saint Petersburg, recently underwent a crucial step in CAR-T therapy at Jiahui International Hospital in Shanghai – apheresis. This process involves collecting T cells from the patient’s body for further genetic modification and amplification. Vladimir expressed appreciation for the professionalism of the treatment team and the transparency of the treatment process, which not only alleviated his anxiety but also increased confidence in the success of the treatment. Jiahui Hospital utilized its advanced facilities and technology to provide Vladimir with a smooth and efficient apheresis experience, ensuring high-quality collection of T cells and laying a solid foundation for the next steps of treatment.

#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART

6 months ago Myeloma , CAR-T

Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy

🎯Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy🎯

⭐ Recently, Professor Li Ping’s team at Tongji Hospital in Shanghai successfully carried out Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) treatment for a relapsed and refractory multiple myeloma (R/RMM) patient. This therapy brings new hope for the treatment of R/RMM patients.🌟 The patient who underwent CAR-T treatment was diagnosed with multiple myeloma in Thailand in July 2021. With a high tumor burden and aggressive disease, despite receiving systemic chemotherapy, monoclonal antibodies, autologous hematopoietic stem cell transplantation (ASCT), and other treatments, the disease recurred multiple times. Within just 2 years of the disease course, the patient developed resistance to multi-line treatments, making it difficult to control the disease effectively.

🌠 As the number of relapses increases in R/RMM patients and the number of treatment lines expands, the response to treatment worsens, and the duration of remission becomes shorter. However, with the approval of the world’s first fully human CAR-T therapy drug, FUCASO (Eque-cel), in mainland China, new hope has undoubtedly been ignited for the treatment of multiple myeloma. Its breakthrough fully human CAR structure not only has low immunogenicity but also rapid dissociation and low exhaustion, allowing patients to return to a higher quality of life with just one treatment.

☄ After evaluation by Professor Li Ping’s team, the patient met the criteria for CAR-T cell therapy. After thorough communication between doctors and the patient and their family, the patient ultimately chose to undergo CAR-T therapy and completed peripheral blood mononuclear cell collection in November 2023.

✨ We will continue to monitor the patient’s treatment progress and provide follow-up reports.

#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Note: Imaging and data have been authorized by the hospital, patients, and patients’ families.

Menu

Tags Archives: Fully human CART

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan